Delving into the Latest Updates on Stromatis Pharma with Synapse

概览

疾病领域	数量

肿瘤	7
内分泌与代谢疾病	1

排名前五的药物类型	数量

单克隆抗体	4
ADC	2
CAR-T	1

排名前五的靶点	数量

CEACAM5 x CEACAM6	3
nectin-4(细胞黏附分子nectin-4)	1
ROR1(受体酪氨酸激酶样孤儿受体1)	1
SFRP2	1
CEACAM5(癌胚抗原相关细胞粘附分子5)	1

关联

7

项与 Stromatis Pharma 相关的药物

ST-442(Stromatis Pharma)

靶点

SFRP2

作用机制

SFRP2拮抗剂

在研机构

Stromatis Pharma

原研机构

Stromatis Pharma

在研适应症

肿瘤

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

CT109-SN-38

靶点

CEACAM5 x CEACAM6

作用机制

CEACAM5拮抗剂 [+1]

在研机构

Stromatis Pharma

原研机构

Stromatis Pharma

在研适应症

胰腺癌

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

CT109-CAR-T(Stromatis Pharma)

靶点

CEACAM5 x CEACAM6

作用机制

CEACAM5拮抗剂 [+1]

在研机构

Stromatis Pharma

原研机构

Stromatis Pharma

在研适应症

肿瘤

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

100 项与 Stromatis Pharma 相关的临床结果

登录后查看更多信息

0 项与 Stromatis Pharma 相关的专利（医药）

登录后查看更多信息

1

项与 Stromatis Pharma 相关的文献（医药）

2024-07-01·Current Cancer Drug Targets

CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells

Article

作者: Guo, Hua-Bei ; Enos, Clinton W ; Spear, Mark R ; Cardenas, Kelly C Arias ; Gineste, Cyrille ; Gelber, Cohava ; Kwon, Yongjun ; Kortchak, Stephanie ; Dolezal, Samuel ; Pincus, Lauren ; Pierce, J Michael ; Furth, Emma ; Austin, Dana E ; Almofeez, Raghad

Background:CEACAM5 and CEACAM6 are glycosylphosphatidylinositol (GPI)- linked members of the carcinoembryonic antigen-related cell adhesion molecule (CEACAM) family, which are frequently upregulated in epithelial cancers where they contribute to invasion, metastasis, immune evasion, and resistance to anoikis. CT109 is a novel antibody with dual specificity to both CEACAM5 and 6.Objective:In this study, we aimed to perform the preclinical characterization of CT109 and antibody- drug conjugate (ADCs) derivatives of CT109, focusing on CT109-SN-38.Methods:CT109’s cognate epitope was characterized by scanning mutagenesis. CT109 specificity and internalization kinetics were assessed by immunoblot and flow cytometry, respectively. Cognate antigen expression prevalence in colorectal cancer and normal tissue arrays was determined by immunohistochemistry. CT109 conjugations were generated by the reaction of reduced CT109 cysteines with maleimide-functionalized payload linkers. In vitro cytotoxic activity of CT109 ADCs was characterized on antigen-positive and negative pancreatic ductal adenocarcinoma cell (PDAC) lines using a luminometric viability assay. In vivo efficacy of CT109-SN-38 was assessed on a PDAC tumor xenograft model at 10 and 25 mg/kg concentrations.Results:CT109 was shown to bind a glycoepitope centered on N309. CT109 is internalized in the CEACAM5+/CEACAM6+ double-positive PDAC line, BxPC-3, with a t1/2 of 2.3 hours. CT109 ADCs elicit a dose and antigen-dependent cytotoxic effect, with CT109-SN-38 exhibiting an IC50 value of 21 nM in BxPC-3 cells. In a BxPC-3 tumor xenograft model, CT109-SN-38 reduced tumor growth and induced regression in 3/10 mice at a concentration 25 mg/kg.Conclusions:These data suggest that further preclinical and clinical development of CT109-SN-38 is warranted.

100 项与 Stromatis Pharma 相关的药物交易

登录后查看更多信息

100 项与 Stromatis Pharma 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月18日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

2

5

临床前

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

CT109-ADC ( CEACAM5 x CEACAM6 )	肿瘤更多	临床前
CT37(Stromatis Pharma) ( CEACAM5 )	肿瘤更多	临床前
CT109-SN-38 ( CEACAM5 x CEACAM6 )	胰腺癌更多	临床前
ST-442(Stromatis Pharma) ( SFRP2 )	肿瘤更多	临床前
CT109-CAR-T(Stromatis Pharma) ( CEACAM5 x CEACAM6 )	肿瘤更多	临床前